Status:
COMPLETED
Effectiveness of Bupropion in Treating Marijuana Dependent Individuals
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Marijuana Abuse
Substance-Related Disorders
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tob...
Detailed Description
A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. This syndrome includes alterations in mood, sleep disturbances, and cognitive performance. Many o...
Eligibility Criteria
Inclusion
- Current marijuana use and dependence
- Marijuana use of at least 5 times in the past 7 days or more than 25 times per month for the 3 years prior to enrollment
- Unsuccessful in a previous attempt to quit marijuana
Exclusion
- Axis I disorder
- Any drug abuse or dependence other than marijuana
- Currently taking antipsychotic or antidepressant medication
- Heavy alcohol drinker (more than 20 drinks per week)
- Current nicotine dependence
- History of a seizure disorder
- Current or prior eating disorder (e.g., bulimia or anorexia nervosa)
- Heavy caffeine use (more than 300 mg per day)
- Life threatening or unstable medical illness
- Pregnant
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00142870
Start Date
March 1 2005
End Date
May 1 2006
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital, Dept. of Psychiatry
Belmont, Massachusetts, United States, 02478 9106